LOXL2 and systemic sclerosis: Similar to these results, previous studies also reported the overexpression of LOX and LOXL-2 in various pathological conditions characterized by fibrotic phenotypes, including IPF, renal fibrosis, cardiac fibrosis, skin aging and systemic sclerosis.